Chong Kun Dang Pharmaceutical Corp. - Company Profile
Powered by 
All the sales intelligence you need on Chong Kun Dang Pharmaceutical Corp. in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Chong Kun Dang Pharmaceutical Corp. fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Chong Kun Dang Pharmaceutical Corp..
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Chong Kun Dang Pharmaceutical Corp (CKD Pharma) manufactures, distributes, imports, and exports prescription drugs, over-the-counter (OTC) drugs, health supplements, and consumer health products. The company's product portfolio includes prescription drugs for the central nervous system, cardiovascular, anti-infective, and oncology therapeutic areas. Its over-the-counter (OTC) drugs include vitamins and minerals, anemia treatments, nonsteroidal anti-inflammatory drugs, liver protective agents, and musculoskeletal and gastrointestinal system remedies. It has a manufacturing facility in Cheonan City, South Korea. The company has a global business presence, with operations in Asia, the Middle East, North Africa, and the European Union. CKD Pharma is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
8, Chungjeong-Ro, Seodaemun-Gu, Seoul, 03742
Website
www.ckdpharm.com
Telephone
82 2 21940300
No of Employees
1,904
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
185750 (KRX)
Revenue (2024)
$1.2B
6.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-28.9%
(2024 vs 2023)
Market Cap*
$612.5M
Net Profit Margin (2024)
XYZ
-33.4%
(2024 vs 2023)
* As of and is in US$
Chong Kun Dang Pharmaceutical Corp. premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Prescription Drugs | Prolia |
| Over-the-Counter Products | Atojet |
| Quasi Drugs | Gliatirin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In December, the company entered into a joint sales agreement with Asleep for Apnotrack, a digital diagnostic aid for sleep apnea. |
| 2025 | Contracts/Agreements | In February, the company entered into a partnership with GC Biopharma to jointly sell neutropenia treatment Neulapeg (pegteograstim). |
| 2024 | Contracts/Agreements | In February, the company entered into an agreement with Healis Therapeutics to develop neuromodulator protein. |
Competitor Comparison
| Key Parameters | Chong Kun Dang Pharmaceutical Corp. | Daewoong Pharmaceutical Co Ltd | Dong-A Socio Holdings Co Ltd | Suheung Capsule Co Ltd | Ildong Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Seoul | Hwaseong | Seoul | Cheongju | Seoul |
| State/Province | Seoul | - | - | - | - |
| No. of Employees | 1,904 | 1,742 | 273 | 727 | 1,433 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Variant Won | Director; Head - Production Division | Executive Board | - | 61 |
| Han Seonguk | Executive Office Manager; Director | Executive Board | - | 55 |
| Lee Seunghwan | Director; Head - Sales Division | Executive Board | - | 59 |
| Lee Yunhan | Head -Audit Office; Director | Executive Board | - | 68 |
| Lee Janghan | President | Senior Management | - | 74 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer